Novartis Ag (NVS) Notes Payables (2016 - 2025)

Novartis Ag has disclosed Notes Payables across 10 years of filings, most recently posting $682.0 million for Q4 2025.

• In Q4 2025, Notes Payables rose 6.23% year-over-year to $682.0 million; the TTM figure through Dec 2025 stood at $682.0 million (up 6.23% YoY), while the FY2025 annual figure was $682.0 million, up 6.23% from the prior year.
• Notes Payables came in at $682.0 million for Q4 2025 at Novartis Ag, up from $642.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $899.0 million in Q4 2021 to a low of $624.0 million in Q4 2023.
• Average Notes Payables over 5 years is $742.0 million, with a median of $682.0 million recorded in 2025.
• Year-over-year, Notes Payables declined 27.69% in 2023 and advanced 6.23% in 2025.
• Over 5 years, Notes Payables stood at $899.0 million in 2021, then slipped by 4.0% to $863.0 million in 2022, then slipped by 27.69% to $624.0 million in 2023, then rose by 2.88% to $642.0 million in 2024, then advanced by 6.23% to $682.0 million in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $682.0 million in Q4 2025, $642.0 million in Q4 2024, and $624.0 million in Q4 2023.